Collegium Pharmaceutical Plans First Quarter 2025 Financial Report
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is gearing up to release its financial results for the first quarter of 2025. The much-anticipated announcement is scheduled to come after the market close on a Thursday in early May. Following the report, the company will engage its stakeholders by holding a live conference call along with a webcast.
Participating in the Call
Investors wishing to join the earnings call can access it by dialing (877) 407-8037 for U.S. callers, or (201) 689-8037 for those located internationally. The session promises to offer valuable insights into Collegium's performance and future strategies, as participants will reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” For those who cannot attend the live call, an audio webcast will be made available shortly after the event concludes, and listeners can find it in the Investors section of the company’s website.
About Collegium Pharmaceutical
Collegium Pharmaceutical is on a mission to emerge as a prominent biopharmaceutical company, deeply dedicated to enhancing the quality of life for individuals coping with serious medical issues. With a robust portfolio, the company has carved a niche for itself in responsible pain management treatments. Notably, Collegium has recently expanded its offerings by acquiring Jornay PM, an important medication aimed at treating ADHD, which signifies a strategic entry into neuropsychiatry.
Strategic Growth
The company’s strategy focuses on not just expanding its commercial portfolio, but also ensuring that Jornay PM becomes a pivotal driver for growth. Collegium’s disciplined investment approach is instrumental in securing a bright future while maximizing returns for shareholders.
Contacting Collegium
Collegium encourages investors and media representatives to reach out for further information or inquiries. Ian Karp serves as the Head of Investor Relations and can be contacted via email at ir@collegiumpharma.com.
Investor Relations Team
For additional insights, investors can connect with Danielle Jesse, who is the Director of Investor Relations, at the same email address mentioned above. The company values open communication and strives to provide timely updates to its stakeholders.
Engagement with Media
Collegium maintains a dedicated team for corporate communications, led by Cheryl Wheeler. Media inquiries can be directed to her email at communications@collegiumpharma.com. This reinforces Collegium's commitment to transparency and accessibility.
Frequently Asked Questions
When will Collegium Pharmaceutical announce its Q1 2025 results?
The announcement is scheduled for a Thursday in early May, after market close.
How can I participate in the earnings call?
You can participate by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers.
What is Jornay PM?
Jornay PM is a medication recently acquired by Collegium that is utilized for the treatment of ADHD, marking the company's entry into neuropsychiatry.
Who can I contact for investor relations?
You can contact Ian Karp, the Head of Investor Relations, at ir@collegiumpharma.com.
What is Collegium’s mission?
The mission of Collegium Pharmaceutical is to enhance the lives of individuals affected by serious medical conditions through innovative treatments.
